Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

axitinib (Rx)Brand and Other Names:Inlyta

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 1mg
  • 5mg
more...

Renal Cell Carcinoma

Indicated for treatment of advanced renal cell carcinoma after failure of 1 prior systemic therapy

Initial dose: 5 mg PO q12hr (see Dosage Modifications)

Dosage Modifications

Dose increase or reduction based on individual safety and tolerability

Dose escalation

  • Criteria: Tolerated for at least 2 consecutive weeks with no adverse reactions (ie, not exceeding grade 2 toxicities) and are normotensive and not receiving antihypertension medications
  • First dose increase: 7 mg PO BID
  • Second dose increase: Using the same criteria, may further increase to 10 mg PO BID

Dose reduction or discontinuation

  • Hypertension: If persistent hypertension occurs despite antihypertensive medications, reduce dose; discontinue if hypertension is severe and persists despite dose reduction
  • Hypertensive crisis: Discontinue axitinib
  • Hemorrhage: If any bleeding requires medical intervention, temporarily interrupt axitinib dose
  • Surgery: Discontinue at least 24 hr prior to scheduled surgery
  • Reversible posterior leukoencephalopathy syndrome: Discontinue axitinib
  • Moderate-to-severe proteinuria: Reduce dose or temporarily interrupt treatment
  • Strong CYP3A4/5 inhibitors: Avoid coadministration if possible, if axitinib must be coadministered, decrease dose by ~50% and then adjust according to safety and tolerance; if strong CYP3A4/5 inhibitor is discontinued, may increase to prior axitinib dose after waiting 3-5 half-lives of the inhibitor

Renal & Hepatic Impairment

Renal impairment

  • No dedicated renal impairment trial has been conducted
  • Based on population pharmacokinetic analyses, no significant difference in clearance observed in patients with pre-existing mild-to-severe renal impairment

Hepatic impairment

  • Mild (Child-Pugh A): No adjustment of initial dose is required
  • Moderate (Child-Pugh B): Decrease initial dose by ~50%; subsequent doses can be increased or decreased based on individual safety and tolerability
  • Severe (Child-Pugh C): Has not been studied

Administration

Administer twice daily approximately 12 hr apart

May be taken with or without food

Swallow whole with a glass of water; do not split, crush, or chew

If patient vomits or misses a dose, an additional dose should not be taken; the next prescribed dose should be taken at the usual time

<18 years: Safety and efficacy not established

In clinical trials, 34% of participants 65 years or older

No overall differences were observed in the safety or efficacy between elderly and younger patients

No dosage adjustment required in elderly patients

Next

Interactions

Interaction Checker

axitinib and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Diarrhea (55%)

            Hypertension (40%)

            Fatigue (39%)

            Decreased appetite (34%)

            Nausea (32%)

            Dysphonia (31%)

            Palmar-plantar erythrodysesthesia syndrome (27%)

            Weight decreased (25%)

            Vomiting (24%)

            Asthenia (21%)

            Constipation (20%)

            Hypothyroidism (19%)

            Cough (15%)

            Mucosal inflammation (15%)

            Arthralgia (15%)

            Stomatitis (15%)

            Dyspnea (15%)

            Abdominal pain (14%)

            Headache (14%)

            Extremity pain (13%)

            Rash (13%)

            Proteinuria (11%)

            Dysgeusia (11%)

            1-10%

            Dry skin (10%)

            Dyspepsia (10%)

            Dizziness (9%)

            Upper abdominal pain (8%)

            Myalgia (7%)

            Pruritus (7%)

            Dehydration (6%)

            Epistaxis (6%)

            Hypercalcemia (6%)

            Anemia (4%)

            Alopecia (4%)

            Hemorrhoids (4%)

            Hematuria (3%)

            Tinnitus (3%)

            Increased lipase (3%)

            Glossodynia (3%)

            Pulmonary embolism (2%)

            Rectal hemorrhage (2%)

            Hemoptysis (2%)

            Erythema (2%)

            DVT (1%)

            Retinal vein occlusion/thrombosis (1%)

            Polycythemia (1%)

            TIA (1%)

            <1%

            Reversible posterior leukoencephalopathy syndrome

            Previous
            Next

            Warnings

            Contraindications

            None

            Cautions

            Hypertension and hypertensive crisis reported in clinical trials, typically within the first month of treatment; blood pressure increases may appear as early as 4 days after initiating; blood pressure should be well controlled before starting therapy; dosage modification or discontinuation of treatment may be required (see Dosage Modification)

            Although rare, arterial thromboembolic events (including deaths) reported during clinical trials

            Venous thromboembolic events (eg, DVT, PE, retinal vein occlusion, retinal vein thrombosis) reported, including deaths

            Hemorrhagic events (eg, cerebral hemorrhage, hematuria, hemoptysis, GI bleeding, melena) may occur

            Rare occurrences of GI perforation and fistula formation reported

            May cause thyroid dysfunction; monitor thyroid function before initiating and periodically throughout therapy

            Stop treatment 24 hr before scheduled surgery

            May cause proteinuria; monitor proteinuria before initiating and periodically throughout therapy

            Elevated liver enzymes reported; monitor ALT, AST, and bilirubin

            Moderate hepatic impairment requires dose reduction (see Dosage modification)

            Coadministration with strong CYP3A4/5 inhibitors or inducers should be avoided if possible (see Dosage modifications)

            Cardiac failure reported with axitinib use; monitor for signs or symptoms of cardiac failure throughout treatment; may require permanent discontinuation of axitinib

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: D; can cause fetal harm when administered to a pregnant woman based on its mechanism of action; axitinib was teratogenic, embryotoxic, and fetotoxic in mice at exposures lower than human exposures at the recommended starting dose

            Lactation: Unknown whether distributed in breast milk; because of the potential for serious adverse reactions in nursing infants from axitinib, a decision should be made whether to discontinue breast feeding or to discontinue the drug, taking into account the importance of the drug to the mother

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Multi-targeted tyrosine kinase inhibitor

            Inhibits receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3

            Absorption

            Bioavailability: 58%

            Peak Plasma Time: 2.5-4.1 hr

            Peak Plasma Concentration: 27.8 ng/mL

            AUC: 265 ng•h/mL

            Distribution

            Protein Bound: >99% (mostly to albumin, moderately to alpha1-acid glycoprotein)

            Vd: 160 L

            Metabolism

            Metabolized primarily by CYP3A4/5 and to a lesser degree by CYP1A2, CYP2C19, and UGT1A1

            Metabolites: Plasma levels detected the N-glucuronide metabolite (50%), sulfoxide metabolite (20%), and 20% unchanged drug

            Elimination

            Half-life: 2.5-6.1

            Total body clearance: 38 L/h

            Excretion: feces 41% (12% unchanged), urine 23% (as carboxylic acid and sulfoxide metabolites)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.